multiple%20myeloma
MULTIPLE MYELOMA

Multiple myeloma is a bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion.

It accounts for 1-2% of all cancers worldwide & mostly affects patients at ages 65-74 years old.

Patient usually presents with bone pain & nonspecific symptoms, or due to abnormalities in laboratory exams.

 

Multiple%20myeloma Signs and Symptoms

Definition

  • A bone marrow disease characterized by the presence of malignant plasma cells, and abnormal serum and/or urine immunoglobulin secondary to clonal plasma cell expansion

Signs and Symptoms

  • Patients usually present with bone pain and fatigue due to anemia
  • Nonspecific symptoms eg nausea, vomiting, malaise, weight loss, generalized body weakness, fatigue

Etiology

  • There are 2 processes being considered to be the root cause of multiple myeloma

Premalignant Stage: Appearance of MGUS

  • Brought about by the cytogenetic abnormalities and/or abnormal cellular response to an antigenic stimulus
  • Malignant transformation of plasma cells leads to production of monoclonal paraprotein (M-protein) composed of single heavy and light chain immunoglobulins
    • Abnormal immunoglobulins include IgG, IgM, IgA, and rarely IgE and IgD
    • Light chain protein κ and λ are also seen
    • These immunoglobulins cause hyperviscosity and end-organ damage
  • Chromosomal aberrations identified with multiple myeloma include del17p13, IgH gene rearrangement at 14q32, 14q32 translocations [t(11;14)(q13;q32), t(4;14)(p16;q32), t(14;16)(q32;q23), t(14;20)(q32;q12)], and chromosome 1 abnormalities
    • These aberrations lead to the development of plasma cell clones 
  • An antigenic stimulus when interpreted by cells [eg toll-like receptors (TLRs) on myeloma cells, interleukin-6 (IL-6)] abnormally causes an increase in plasma cells, thereby causing chromosomal changes leading to plasma cell clones and abnormally produced immunoglobulins

Disease Progression from MGUS to Multiple Myeloma

  • Triggering factors that contribute to the development of MGUS into multiple myeloma include secondary cytogenetic aberrations (secondary IgH translocation, Ras mutations, activation of the NF κ B pathway), abnormalities in the cell cycle pathway, interrupted apoptosis, and various factors affecting the bone marrow

Risk Factors

  • Age (increases risk)
  • Immunosuppression
  • Environmental exposures
  • Gender (more common in men)
  • Occupational exposure to toxic substances such as radiation, solvents, herbicides, insecticides

Epidemiology

  • Accounts for 1-2% of all cancers worldwide
    • 2nd most frequent hematologic malignancy in the US, with rapidly increasing incidence rate in Asia
  • Median age of onset is 69 years old

Pathophysiology

  • Always preceded by a premalignant stage, monoclonal gammopathy of undetermined significance (MGUS)
    • Only 10% of patients with newly diagnosed multiple myeloma have a documented history of pre-existing MGUS since patients with MGUS are asymptomatic
    • Rate of progression of MGUS to multiple myeloma is 1% per year
    • Non-IgM immunoglobulin MGUS (non-IgM MGUS) makes up 80% of premalignant multiple myeloma
    • Light-chain immunoglobulin MGUS makes up 20% of premalignant multiple myeloma
    • IgM immunoglobulin MGUS usually develops into Waldenström macroglobulinemia but may rarely evolve into multiple myeloma (IgM myeloma)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).